Establishment of extensive artificial intelligence models for kinase inhibitor prediction: Identification of novel PDGFRB inhibitors

Attwood, 2021, Trends in kinase drug discovery: targets, indications and inhibitor design, Nat. Rev. Drug Discov., 20, 839, 10.1038/s41573-021-00252-y Roskoski, 2022, Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update, Pharmacol. Res., 175, 10.1016/j.phrs.2021.106037 Lovly, 2014, Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies, Clin. Cancer Res., 20, 2249, 10.1158/1078-0432.CCR-13-1610 Berginski, 2021, The Dark Kinase Knowledgebase: an online compendium of knowledge and experimental results of understudied kinases, Nucleic Acids Res., 49, D529, 10.1093/nar/gkaa853 Meng, 2011, Molecular docking: a powerful approach for structure-based drug discovery, Curr. Comput. Aided Drug Des., 7, 146, 10.2174/157340911795677602 Polishchuk, 2017, Interpretation of quantitative structure-activity relationship models: past, present, and future, J. Chem. Inf. Model., 57, 2618, 10.1021/acs.jcim.7b00274 Vamathevan, 2019, Applications of machine learning in drug discovery and development, Nat. Rev. Drug Discov., 18, 463, 10.1038/s41573-019-0024-5 Merget, 2017, Profiling prediction of kinase inhibitors: toward the virtual assay, J. Med. Chem., 60, 474, 10.1021/acs.jmedchem.6b01611 Li, 2020, Deep learning enhancing kinome-wide polypharmacology profiling: model construction and experiment validation, J. Med. Chem., 63, 8723, 10.1021/acs.jmedchem.9b00855 Rodríguez-Pérez, 2019, Multitask machine learning for classifying highly and weakly potent kinase inhibitors, ACS Omega, 4, 4367, 10.1021/acsomega.9b00298 Buchwald, 2011, Predicting a small molecule-kinase interaction map: a machine learning approach, J. Cheminf., 3, 22, 10.1186/1758-2946-3-22 Bao, 2023, Kinome-wide polypharmacology profiling of small molecules by multi-task graph isomorphism network approach, Acta Pharm. Sin. B, 13, 54, 10.1016/j.apsb.2022.05.004 Pogodin, 2018, How to achieve better results using PASS-based virtual screening: case study for kinase inhibitors, Front. Chem., 6, 133, 10.3389/fchem.2018.00133 Cichonska, 2021, Crowdsourced mapping of unexplored target space of kinase inhibitors, Nat. Commun., 12, 3307, 10.1038/s41467-021-23165-1 Yang, 2019, Concepts of artificial intelligence for computer-assisted drug discovery, Chem. Rev., 119, 10520, 10.1021/acs.chemrev.8b00728 Domingo-Almenara, 2019, The METLIN small molecule dataset for machine learning-based retention time prediction, Nat. Commun., 10, 5811, 10.1038/s41467-019-13680-7 Carracedo-Reboredo, 2021, A review on machine learning approaches and trends in drug discovery, Comput. Struct. Biotechnol. J., 19, 4538, 10.1016/j.csbj.2021.08.011 Mendez, 2019, ChEMBL: towards direct deposition of bioassay data, Nucleic Acids Res., 47, D930, 10.1093/nar/gky1075 Kim, 2019, PubChem 2019 update: improved access to chemical data, Nucleic Acids Res., 47, D1102, 10.1093/nar/gky1033 Tang, 2014, Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis, J. Chem. Inf. Model., 54, 735, 10.1021/ci400709d Drewry, 2014, Seeding collaborations to advance kinase science with the GSK published kinase inhibitor set (PKIS), Curr. Top. Med. Chem., 14, 340, 10.2174/1568026613666131127160819 Christmann-Franck, 2016, Unprecedently large-scale kinase inhibitor set enabling the accurate prediction of compound-kinase activities: a way toward selective promiscuity by design?, J. Chem. Inf. Model., 56, 1654, 10.1021/acs.jcim.6b00122 Landrum, 2013 Berthold, 2009, KNIME-the Konstanz information miner: version 2.0 and beyond, AcM SIGKDD explorations Newsletter, 11, 26, 10.1145/1656274.1656280 Pedregosa, 2011, Scikit-learn: machine learning in Python, J. Mach. Learn. Res., 12, 2825 Chollet, 2015 Morgan, 1965, The generation of a unique machine description for chemical structures-A technique developed at chemical abstracts service, J. Chem. Doc., 5, 107, 10.1021/c160017a018 Bradley, 1997, The use of the area under the ROC curve in the evaluation of machine learning algorithms, Pattern Recogn., 30, 1145, 10.1016/S0031-3203(96)00142-2 Golbraikh, 2014, Data set modelability by QSAR, J. Chem. Inf. Model., 54, 1, 10.1021/ci400572x Yang, 2020, On hyperparameter optimization of machine learning algorithms: theory and practice, Neurocomputing, 415, 295, 10.1016/j.neucom.2020.07.061 Yuen, 2021, Universal activation function for machine learning, Sci. Rep., 11, 10.1038/s41598-021-96723-8 Keskar, 2016 Chuang, 2020, Learning molecular representations for medicinal chemistry, J. Med. Chem., 63, 8705, 10.1021/acs.jmedchem.0c00385 Kolluri, 2022, Machine learning and artificial intelligence in pharmaceutical research and development: a review, AAPS J., 24, 19, 10.1208/s12248-021-00644-3 Martin, 2002, Do structurally similar molecules have similar biological activity?, J. Med. Chem., 45, 4350, 10.1021/jm020155c Dowden, 2019, Trends in clinical success rates and therapeutic focus, Nat. Rev. Drug Discov., 18, 495, 10.1038/d41573-019-00074-z Lyu, 2023, Modeling the expansion of virtual screening libraries, Nat. Chem. Biol., 10.1038/s41589-022-01234-w Hofer, 2004, Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors, Neoplasia, 6, 503, 10.1593/neo.04157 Xie, 2020, Comprehensive review of targeted therapy for colorectal cancer, Signal Transduct. Targeted Ther., 5, 22, 10.1038/s41392-020-0116-z Kanaan, 2017, Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease, Eur. Respir. Rev., 26, 10.1183/16000617.0061-2017 Lin, 2022, Identification and analysis of a selective DYRK1A inhibitor, Biomed. Pharmacother., 146, 10.1016/j.biopha.2021.112580 Lin, 2022, Discovery of a novel cyclin-dependent kinase 8 inhibitor with an oxindole core for anti-inflammatory treatment, Biomed. Pharmacother., 146, 10.1016/j.biopha.2021.112459 Baell, 2010, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem., 53, 2719, 10.1021/jm901137j Bickerton, 2012, Quantifying the chemical beauty of drugs, Nat. Chem., 4, 90, 10.1038/nchem.1243 Klaeger, 2017, The target landscape of clinical kinase drugs, Science, 358, 10.1126/science.aan4368 Leissing, 2020, Structure driven compound optimization in targeted protein degradation, Drug Discov. Today Technol., 37, 73, 10.1016/j.ddtec.2020.11.005 Schwartz, 2011, Protein kinase biochemistry and drug discovery, Bioorg. Chem., 39, 192, 10.1016/j.bioorg.2011.07.004 Metz, 2018, Coral: clear and customizable visualization of human kinome data, Cell Syst, 7, 347, 10.1016/j.cels.2018.07.001